

Vaccination calendar

30.03.2021

Conditions for the vaccination calendar(1/2)

- The number of vaccines received and distributed has changed as a result of updated figures from the vaccine manufacturers
- The deliveries from the vaccine manufacturers are given per quarter to the NIPH. If the NIPH has not received confirmed figures for monthly deliveries, the quarterly delivery is divided over three months as an estimate. Adjustment to these figures in some months does not indicate that the supplier is not delivering as planned.
- It is assumed that there will be 90 % uptake for dose 1 and 95 % for dose 2 for all groups, with the exception of healthcare workers where 100 % uptake is assumed
- The distribution key is changed from, and including, week 12
 - The distribution key for mRNA vaccines, as well as J&J, CureVac and Novavax is changed from «over 65 years» to «over 18 years» plus a geographical prioritisation of 20% to the municipalities: Oslo, Lørenskog, Sarpsborg, Fredrikstad and Moss
 - The distribution key for AstraZeneca is changed from «under 65 years» to «over 18 years», plus a geographical prioritisation of 20% to the municipalities: Oslo, Lørenskog, Sarpsborg, Fredrikstad and Moss
 - For weeks 11 – 13 all the Moderna doses received will be used for geographical prioritisation of mRNA vaccines. This entails an implicit geographical prioritisation of mRNA vaccines significantly above 20%, and covers geographical prioritisation for several weeks ahead. Further geographical prioritisation is thus not carried out until implicit geographical prioritisation is down to the desired level of 20%.
 - A geographical prioritisation of vaccine doses will be made until the population group «over 18 years of age» is 95 % fully vaccinated in the municipalities that are prioritised. The doses to the five municipalities that are prioritised are taken from 328 other municipalities
- The minimum number of doses for a municipality is set to one vial from, and including, week 15
- The number of healthcare workers is 380 000. This is split into two groups: The specialist healthcare service in total: 140 000 and the primary healthcare service in total: 240 000
- The primary health care service will receive 20 % of the available doses every week until full vaccination. The specialist healthcare service will receive approximately 40 000 doses a month until full vaccination
- The doses distributed to inpatients are included in the 140 000 doses to be distributed to the specialist healthcare service

Conditions for the vaccination calendar (2/2)

- Some high-risk groups over the age of 18 do not receive AstraZeneca
- AstraZeneca doses are not being despatched in weeks 11 - 15, neither dose 1 nor dose 2. The pause of AZ for five weeks is assumed to not affect the calendar much, as these doses would be distributed in week 16 instead so that the total number of AZ doses distributed would remain the same.
- Imported doses outside the European collaboration is assumed to be 0 for the whole period
- The extended interval between dose 1 and dose 2 is changed to the following number of weeks from, and including, week 11:
 - Pfizer – 6 weeks
 - Moderna – 6 weeks
 - AstraZeneca – 12 weeks
 - CureVac – 6 weeks
 - Novavax – 6 weeks
- The number of weeks between doses 1 and 2 will be reduced towards the end of the period in order to complete vaccination of the population groups earlier. This applies to: Pfizer (3 weeks), Moderna (4 weeks) and AstraZeneca (8 weeks) The time for this reduction will be adjusted so that the last dose of the J&J vaccine will be administered in the same week as the last dose of all the other vaccine types. For example, with full vaccination in week 29, the last dose 1 of Pfizer will be distributed in week 26 (3 weeks before), Moderna in week 25 (4 weeks before) and AstraZeneca in week 21 (8 weeks before).
- Long-term stock of the different types of vaccine is somewhat reduced and changed from the last vaccination calendar:
 - Pfizer: 16 000 doses
 - Moderna: 1 000 doses. 50 % of the doses will no longer be reserved, everything will be despatched.
 - AstraZeneca: 1 000 doses
 - J&J: everything sent out
 - Curevax: 10 000 doses
 - Novavax: 10 000 doses

Description of the scenarios

Comments to the changes from version 12.03.2021 to version 30.03.2021

Conservative scenario: includes the vaccine types: Pfizer, Moderna, AstraZeneca and J&J. Astra Zeneca is no longer limited to 200 000 doses per month in the period April – September

Optimistic scenario: includes the vaccine types: as the conservative scenario, plus CureVac and Novavax

- Change in conditions: Change in time of full vaccination is mainly related to the following change in conditions;
 - In updated scenarios, vaccination with dose 2 is completed in the same week as the last dose 1 of J&J is distributed. In other words, J&J is prioritised as we approach the end of the immunisation programme. In the version from 12.03, the same logic applied, but with Pfizer as the starting point rather than J&J.
 - In updated scenarios, the last dose 1 of other vaccine types is distributed x number of weeks before the week in which the last J&J is administered (an iterative process to determine this week), where x is the number of weeks between dose 1 and 2 for each vaccine type. x is thus 3 weeks for Pfizer, 4 for Moderna and 8 for AZ. The reduction will happen in advance of this.
- In addition, the following changes will affect the calendar:
 - Change in the number of vaccine doses received.
 - Reduction of long-term stock of Pfizer to 16 000 doses, corresponding to one pack per hospital pharmacy.
 - Despatch of all Moderna doses received, in contrast to previous versions where 50 % was withheld
- Note that the conservative and optimistic scenarios are assumed to be completed with vaccination in the same week. The reason for this is the following:
 - The only change from a conservative to optimistic scenario is that Curevac and Novavax are included. Doses of Curevac and Novavax are expected to be received from week 27 and week 23, respectively, and for both types of vaccine, a 6-week interval between doses 1 and 2 is assumed.
 - If you follow the main assumption with completion in week 28, week 22 will be the last week where we distribute dose 1 of Curevac and Novavax. As the first delivery is assumed to be week 23, no doses of these vaccine types will be used. The consequence is that the conservative and optimistic scenario will be the same.

Vaccination scenarios

30th March – conservative and optimistic


Vaccination scenario

CONSERVATIVE SCENARIO

When do we expect to be able to vaccinate different groups against COVID-19?

VERSION 30th MARCH
THE CALENDAR IS PRELIMINARY
AND WILL BE UPDATED
REGULARLY

- This scenario includes the conservative delivery forecasts for Pfizer-BioNTech, Moderna, AstraZeneca and Janssen.
- The figures are uncertain and the scenario gives a preliminary picture.
- The vaccination scenario shows a simplified national average where we assume that the recommended prioritisations are followed and that the municipalities vaccinate at the same rate.



¹ See detailed information on the last page


Vaccination scenario

OPTIMISTIC SCENARIO

When do we expect to be able to vaccinate different groups against COVID-19?

VERSION 30th MARCH
THE CALENDAR IS PRELIMINARY
AND WILL BE UPDATED REGULARLY

- This scenario includes the delivery forecasts for Pfizer-BioNTech, Moderna, AstraZeneca, Janssen, CureVac and Novavax. For some of these it is still unclear when, and for which groups, approval will come.
- The figures are uncertain and the scenario gives a preliminary picture.
- The vaccination scenario shows a simplified national average where we assume that the recommended prioritisations are followed and that the municipalities vaccinate at the same rate.



¹ See detailed information on the last page

Vaccination scenario

Assumptions and background information

VERSION 30 MARCH

For further information about the Coronavirus Immunisation Programme, see <https://www.fhi.no/en/id/vaccines/cvp/>

Assumptions and background information

- Vaccines from AstraZeneca, Pfizer/BioNTech and Moderna are given to people over 18 years.
- Certain risk groups, including people with organ transplants will only be offered mRNA vaccines.
- An assessment is ongoing whether people between the ages of 16 and 18 should be offered vaccination with the available vaccines.
- It is assumed in these scenarios that 380,000 health personnel are prioritised together with people ≥ 85 years of age. Until further notice, it is assumed that approximately 40,000 or more doses are allocated per month for the specialist health service, and up to 20% of doses sent to municipalities are reserved for health personnel. This is a preliminary assumption and will be assessed on an ongoing basis.
- It is assumed in the scenarios that the municipalities follow prioritisation recommendations and that they vaccinate at the same rate. In practice, there will be variation between the municipalities.
- In the scenarios, it is assumed that 90% of all those who are offered a vaccine take it, and that 95% of these again show up for a second dose. Actual vaccine uptake may differ and will be assessed on an ongoing basis.
- The distribution key changes from 1 April according to NIPH's recommendations. Geographical prioritisation to Oslo, Lørenskog, Fredrikstad, Moss and Sarpsborg introduced from (and including) week 11.²

Size of prioritised groups³

	<i>Antall</i>
Residents in nursing homes	40 000
Health personnel	380 000
85 years and over	115 000
75-84 years	290 000
65-74 years, and 18-64 with underlying diseases and conditions with high risk of severe disease course ³	565 000
55-64 years with underlying diseases and conditions ³	110 000
45-54 years with underlying diseases and conditions ³	100 000
18-44 years with underlying diseases and conditions ³	110 000
55-64 years	415 000
45-54 years	565 000
18-44 years ⁴	1 560 000

Vaccine deliveries (doses) in these scenarios – version 30 March 2021

	<i>December</i>	<i>January</i>	<i>February</i>	<i>March</i>	<i>April</i>	<i>May</i>	<i>June</i>	<i>July</i>
Pfizer-BioNTech ⁴	53	187	210	360	590	570	1 180	710
Moderna		10	30	70	70	140	190	510
AstraZeneca (con-opt)			90	260	230	340	220	220
J&J/Janssen					60	230	680	700
CureVac+Novavax (opt)							70	250

² <https://www.fhi.no/contentassets/1af4c6e655014a738055c79b72396de8/svar-pa-tilleggsoppdrag-til-delleveranse-pa-oppdrag-8-.pdf>

³ Read more about definition of risk groups: [fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)

⁴ Vaccination arrangements for age group 18-44 years are being assessed and not yet fully decided.